Fangfang Xie

Fangfang Xie

Auto-generated profile, based on publicly available information

Fangfang Xie

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Journal of Global Health
Verified
Journal Article
Open access
JCJiahe Cui
Jiahe Cui
FXFangfang Xie
Fangfang Xie
HYHongyu Yue
Hongyu Yue
CXChaoqun Xie
Chaoqun Xie
JMJianwen Ma
Jianwen Ma
FYFei Yao
Fei Yao
Constipation is typically caused by the dysfunction of the colon or rectum, pelvic floor, and anus, leading to difficult defecation, incomplete defecation volume, and less than three bowel movements per week. Patients may also experience other symptoms such as abdominal discomfort, abdominal distension, straining during defecation, and anorectal obstruction [1]. The global prevalence of functional […]

13 June 2025 in Journal of Global Health
Verified
Journal Article
Open access
XCXiaofeng Cui
Xiaofeng Cui
FXFangfang Xie
Fangfang Xie
JCJiahe Cui
Jiahe Cui
YTYukui Tian
Yukui Tian
XBXue Bai
Xue Bai
FYFei Yao
Fei Yao
Knee osteoarthritis (KOA), a prevalent chronic degenerative joint disease, is pathologically characterised by progressive degradation of articular cartilage. This structural deterioration triggers subchondral bone remodelling and synovial tissue changes, resulting in periarticular pain, oedema, and restricted range of motion. Functional impairment and persistent nociception remain the cardinal clinical manifestations that determine the severity of the […]

26 February 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
FXFangfang Xie
Fangfang Xie
YYYan-li You
Yan-li You
YGYuanjia Gu
Yuanjia Gu
JXJiatuo Xu
Jiatuo Xu
FYFei Yao
Fei Yao
Background: Chronic fatigue syndrome (CFS) is a debilitating multisystem disorder that can lead to various pathophysiological abnormalities and symptoms, including insomnia, gastrointestinal disorders, and anxiety. Due to the side effects of currently available drugs, there is a growing need for safe and effective nondrug therapies. The Prolong Life With Nine Turn (PLWNT) Qigong method is a system of mind-body exercise with restorative benefits that can alleviate the clinical symptoms of CFS and impart a significant inhibitory effect. Various studies have proven the treatment efficacy of PLWNT; however, the impact on insomnia, gastrointestinal disorders, and anxiety in patients with CFS has not yet been investigated. Objective: This study aims to evaluate the efficacy and safety of the PLWNT method in terms of its effects on fatigue, insomnia, anxiety, and gastrointestinal symptoms in patients with CFS. Methods: We will conduct a randomized, analyst-blinded, parallel-controlled trial with a 12-week intervention and 8-week follow-up. A total of 208 patients of age 20-60 years will be recruited. The patients will be randomly divided into a PLWNT Qigong exercise group (PLWNT Group) and a control group treated with cognitive behavioral therapy at a ratio of 1:1. Participants from the treatment groups will be taught by a highly qualified professor at the Shanghai University of Traditional Chinese Medicine once a week and will be supervised via web during the remaining 6 days at home, over 12 consecutive weeks. The primary outcome will be the Multidimensional Fatigue Inventory 20, while the secondary outcomes include the Pittsburgh Sleep Quality Index, Gastrointestinal Symptom Rating Scale, Hospital Anxiety and Depression Scale, functional magnetic resonance imaging, gut microbiota, and peripheral blood. Results: The study was approved by the ethics committee of Shanghai Municipal Hospital of Traditional Chinese Medicine in March 2022 (Ethics Approval Number 2022SHL-KY-05). Recruitment started in July 2022. The intervention is scheduled to be completed in December 2024, and data collection will be completed by the end of January 2025. Over the 3-year recruitment period, 208 participants will be recruited. Data management is still in progress; therefore, data analysis has yet to be performed. Conclusions: This randomized trial will evaluate the effectiveness of the PLWNT method in relieving fatigue, insomnia, anxiety, and gastrointestinal symptoms in patients with CFS. If proven effective, it will provide a promising alternative intervention for patients with CFS. Trial Registration: China Clinical Trials Registry ChiCTR2200061229; https://www.chictr.org.cn/showproj.html?proj=162803

12 June 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JMJianwen Ma
Jianwen Ma
GGGuang-xin Guo
Guang-xin Guo
HYHongyu Yue
Hongyu Yue
CXChaoqun Xie
Chaoqun Xie
FXFangfang Xie
Fangfang Xie
FYFei Yao
Fei Yao
Introduction Knee osteoarthritis (KOA) is one of the most common osteoarthritis, imposing substantial economic and medical burdens on both individuals and society. In China, Tuina has been selected as a complementary and alternative therapy to relieve knee pain and dysfunction symptoms. However, the current evidence is insufficient to support the efficacy of Tuina therapy in addressing knee pain and improving physical function. The trial aims to compare the effectiveness of Tuina with celecoxib, which is considered as the standard treatment, and to assess its potential as an alternative therapy through changes in outcome measures. Methods and analysis A total of 360 KOA patients aged between 40 and 70 years and classified as Kellgren and Lawrence grades I–II will be recruited from eight subcentral hospitals. The participants will be randomly assigned to either the treatment group (Tuina, Biw) or the control group (celecoxib, Qd), with both groups undergoing a 4-week intervention phase followed by an 8-week follow-up phase. The primary outcome is the change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale at week 4 compared with baseline. Secondary outcomes including WOMAC stiffness and function subscales, WOMAC total score, 36-item Short-Form Health Survey, Timed Up and Go test, Short Physical Performance Battery, gait analysis parameters and pain medication records will be assessed at weeks 4, 8 and 12. Any adverse events that occur during the trial will be promptly recorded. Ethics and dissemination This study has been approved by the Ethics Committee of Shanghai Municipal Hospital of Traditional Chinese Medicine (2023SHL-KY-16-01, 2023SHL-KY-16-02). Written informed consent will be obtained from all participants. Study results will be disseminated through peer-reviewed journals and conference presentations. Trial registration number ChiCTR2300069416.

24 December 2025 in BMJ Open
Verified
Journal Article
Open access
JCJiahe Cui
Jiahe Cui
HHHaotian Han
Haotian Han
HYHongyu Yue
Hongyu Yue
CXChaoqun Xie
Chaoqun Xie
JMJianwen Ma
Jianwen Ma
FYFei Yao
Fei Yao
Introduction: Chronic insomnia is a pressing public health issue that significantly affects patients’ quality of life. In China, Prolong Life With Nine Turn-Method (PLWNT) Qigong exercise has long been used to improve sleep quality, yet evidence that supports its efficacy for chronic insomnia treatment remains lacking. The aim of this study is to evaluate the effectiveness and safety of the PLWNT qigong exercise for treating chronic insomnia and its relationship with hyperarousal. Methods and analysis: This multi-centre randomised controlled trial will recruit 348 eligible patients from three hospitals in Shanghai. Participants will be randomly assigned to either the treatment group (PLWNT qigong exercise) or the control group (cognitive behavioural therapy). The treatment will occur once a week for 12 weeks, followed by an 8-week follow-up phase. The primary outcome is the change in the total Pittsburgh Sleep Quality Index (PSQI) score from baseline to week 12. The secondary outcomes are the scores on the Hyperarousal Scale (HAS), Insomnia Severity Index (ISI), Multidimensional Fatigue Inventory 20 (MFI-20), Hospital Anxiety and Depression (HADS), Medical Outcome Trust 36–Item Short Form Health Survey (SF–36) and Gastrointestinal Symptom Rating Scale (GSRS), gut microbiota, actigraphy, sleep diary, cortisol, adrenocorticotrophic hormone, corticotropin-releasing hormone, polysomnography and functional MRI. All adverse events during the trial will be promptly recorded and assessed. The PSQI, HAS, ISI, MFI-20, HADS, SF–36 and GSRS will be evaluated at baseline, 6 weeks post-treatment and 12 weeks post-treatment, as well as at the 4- week and 8- week follow-ups. Other outcomes will only be evaluated at baseline and 12 weeks post-treatment. Ethics and dissemination: The trial has been approved by the Ethics Committee of the Shanghai Municipal Hospital of Traditional Chinese Medicine (2024SHL-KY-92–01). Written informed consent was obtained from all participants before their involvement in the trial. Results of this study will be published in peer-reviewed journals or at conferences. Trial registration number: ITMCTR2024000534.

12 December 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
CXChaoqun Xie
Chaoqun Xie
FXFangfang Xie
Fangfang Xie
JMJianwen Ma
Jianwen Ma
HYHongyu Yue
Hongyu Yue
YYYan-li You
Yan-li You
FYFei Yao
Fei Yao
Background: Chronic insomnia (CI) is a mind-body disease that is commonly defined as a state of having disturbed daytime activities due to poor nighttime sleep quality. Baduanjin qigong (BDJQG) is widely used for CI in China. However, there is little scientific evidence to evaluate its effects on the hyperarousal state, which is closely associated with improved sleep quality. Objective: The objective of the trial is to assess the therapeutic effects of BDJQG on sleep quality in patients with CI. Methods: A randomized controlled trial will be conducted on 86 patients, who will be divided into a BDJQG group and a cognitive behavioral therapy for insomnia group at a ratio of 1:1. Interventions in both groups will be given to the participants 7 times a week for 8 weeks, and the participants will be followed up for 4 weeks. The primary outcome is the change in the Pittsburgh Sleep Quality Index from baseline to week 8. The secondary outcomes are the changes in the Hyperarousal Scale, Insomnia Severity Index, Fatigue Scale-14, wrist actigraphy, salivary cortisol level, and functional magnetic resonance imaging from baseline to week 8. All main analyses will be carried out on the basis of the intention-to-treat principle. Results: This study was funded from January 2023. As of the submission of the manuscript, there were 86 participants. Data collection began in April 2023 and will end in January 2024. Data analysis is expected to begin in January 2024, with the publication of results expected in February 2024. Conclusions: This study will present data concerning the clinical effects of BDJQG on CI. The results will help to demonstrate whether BDJQG is an effective therapy for improving sleep quality in association with a decreased hyperarousal level as a possible underlying mechanism. This study will provide much-needed knowledge for complementary and alternative therapy for patients with CI. Trial Registration: China Clinical Registration Agency ChiCTR2300069241; https://chictr.org.cn/bin/project/ChiCTR2300069241 International Registered Report Identifier (IRRID): PRR1-10.2196/53501